𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Differential transactivation by the androgen receptor in prostate cancer cells

✍ Scribed by Snoek, Robert; Bruchovsky, Nicholas; Kasper, Susan; Matusik, Robert J.; Gleave, Martin; Sato, Naohide; Mawji, Nasrin R.; Rennie, Paul S.


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
232 KB
Volume
36
Category
Article
ISSN
0270-4137

No coin nor oath required. For personal study only.

✦ Synopsis


BACKGROUND.

The purpose of this study was to determine the contribution of different transactivating regions of the androgen receptor (AR) to the induction of androgen-regulated promoters in poorly (PC3 cells) and well-differentiated (LNCaP cells) prostate cancer cell lines. METHODS. PC3 and LNCaP cells were co-transfected with plasmids expressing full-length AR or deletion mutants together with luciferase reporters linked to the probasin (PB) and PSA promoters; as well as to ARR 3 tk, a PB-derived recombinant promoter. RESULTS. Androgen induction of the ARR 3 tk promoter in the presence of AR was 8-to 10-fold higher than that seen with the PB promoter. Activation of ARR 3 tk was greatest with an androgen-independent construct in which the first 231 amino acids and the ligand binding domain had been removed, indicating that this promoter is more responsive to activating functions in the N-terminal domain than in the ligand binding domain. By comparison, induction of the PB promoter was greatest with the full-length AR, which suggests that the ligand binding domain also makes a major contribution to the activation of this promoter. In similar analyses with the PSA promoter, AR regions required for promoter induction was dependent on the host cell type. In PC3 cells, the predominant AR transactivation function was androgen-independent and resided in the N-terminal domain, whereas in LNCaP cells, the highest level of induction was androgen dependent and also required participation of the ligand binding domain. CONCLUSIONS. Our results indicate that the relative utilization of transactivating functions in N-terminal and ligand binding domains of the AR is promoter and cell specific.


πŸ“œ SIMILAR VOLUMES


Calpain-mediated androgen receptor break
✍ Huanjie Yang; Shalini Murthy; Fazlul H. Sarkar; Shijie Sheng; G. Prem-Veer Reddy πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 210 KB

## Abstract Since androgen receptor (AR) plays an important role in prostate cancer development and progression, androgen‐ablation has been the frontline therapy for treatment of advanced prostate cancer even though it is rarely curative. A curative strategy should involve functional and structural

Gene expression changes following androg
✍ Iris E. Eder; Petra Haag; Mark Basik; Spyro Mousses; Jasmin Bektic; Georg Bartsc πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 355 KB

## Abstract We have shown recently that inhibition of androgen receptor (AR) expression with an antisense AR oligonucleotide (ODN) inhibits LNCaP prostate tumor cells in vitro as well as in vivo. In this study, we investigated gene expression changes that occur after AR signaling blockade, either t

Androgen receptor modifications in prost
✍ Rute B. Marques; Sigrun Erkens-Schulze; Corrina M. de Ridder; Karin G. Hermans; πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 392 KB

## Abstract To study the mechanisms whereby androgen‐dependent tumors relapse in patients undergoing androgen blockade, we developed a novel progression model for prostate cancer. The PC346C cell line, established from a transurethral resection of a primary tumor, expresses wild‐type (wt) androgen

Tributyrin induces differentiation, grow
✍ Simone Maier; Ella Reich; Renate Martin; Max Bachem; Vedat Altug; Richard E. Hau πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 321 KB πŸ‘ 2 views

Progression to androgen independence remains the main problem that impacts on survival and quality of life in prostate cancer patients. We have investigated the potency of tributyrin, an orally available prodrug of butyrate, to induce growth arrest, differentiation and apoptosis in LNCaP, PC-3 and T